Tianfeng Xu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 23

Top Topics

Estrogen Receptor

Anti Inflammatory

Top Venues

Journal of medicinal chemistry

ACS medicinal chemistry letters

This page only lists publications with an associated author ORCID identifier.

Publications

Hualin Zhang, Yutong Tu, Zhaofan Tao, Lixin Gao, Shengjie Huang, Mingshan Gao, Jialuo Mao, Yang Zhou, Yupeng Li, Jia Li, Yubo Zhou, Tianfeng Xu
Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors. ACS medicinal chemistry letters 15 (8) (2024)
Changwei Wang, Mi Wang, Yu Wang, Rohan Kalyan Rej, Angelo Aguilar, Tianfeng Xu, Longchuan Bai, Jelena Tošović, Donna McEachern, Qiuxia Li, Farzad Sarkari, Bo Wen, Duxin Sun, Shaomeng Wang
Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9. Journal of medicinal chemistry (2024)
Changwei Wang, Mi Wang, Yu Wang, Rohan Kalyan Rej, Angelo Aguilar, Tianfeng Xu, Longchuan Bai, Jelena Tošović, Donna McEachern, Qiuxia Li, Farzad Sarkari, Bo Wen, Duxin Sun, Shaomeng Wang
Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9. Journal of medicinal chemistry 67 (16) (2024)
Chuan Zhou, Zisheng Fan, Yuejiao Gu, Zhiming Ge, Zhaofan Tao, Rongrong Cui, Yupeng Li, Guizhen Zhou, Ruifeng Huo, Mingshan Gao, Dan Wang, Wei He, Mingyue Zheng, Sulin Zhang, Tianfeng Xu
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS G12D . Journal of medicinal chemistry 67 (2) (2024)
Zhixiang Chen, Mi Wang, Dimin Wu, Longchuan Bai, Tianfeng Xu, Hoda Metwally, Yu Wang, Donna McEachern, Lijie Zhao, Ruiting Li, John Takyi-Williams, Meilin Wang, Lu Wang, Qiuxia Li, Bo Wen, Duxin Sun, Shaomeng Wang
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression. Journal of medicinal chemistry 67 (7) (2024)
Chuan Zhou, Zisheng Fan, Yuejiao Gu, Zhiming Ge, Zhaofan Tao, Rongrong Cui, Yupeng Li, Guizhen Zhou, Ruifeng Huo, Mingshan Gao, Dan Wang, Wei He, Mingyue Zheng, Sulin Zhang, Tianfeng Xu
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS G12D . Journal of medicinal chemistry (2024)
Huajie Li, Zhiming Ge, Kexin Lin, Wei He, Qinyu Chu, Mingyue Zheng, Sulin Zhang, Tianfeng Xu
Design, Synthesis, and Bioevaluation of Transcriptional Enhanced Assocciated Domain (TEAD) PROTAC Degraders. ACS medicinal chemistry letters 15 (5) (2024)
Huajie Li, Zhiming Ge, Kexin Lin, Wei He, Qinyu Chu, Mingyue Zheng, Sulin Zhang, Tianfeng Xu
Design, Synthesis, and Bioevaluation of Transcriptional Enhanced Assocciated Domain (TEAD) PROTAC Degraders. ACS medicinal chemistry letters 15 (5) (2024)
Chuan Zhou, Zisheng Fan, Yuejiao Gu, Zhiming Ge, Zhaofan Tao, Rongrong Cui, Yupeng Li, Guizhen Zhou, Ruifeng Huo, Mingshan Gao, Dan Wang, Wei He, Mingyue Zheng, Sulin Zhang, Tianfeng Xu
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS G12D . Journal of medicinal chemistry 67 (2) (2024)
Changwei Wang, Mi Wang, Yu Wang, Rohan Kalyan Rej, Angelo Aguilar, Tianfeng Xu, Longchuan Bai, Jelena Tošović, Donna McEachern, Qiuxia Li, Farzad Sarkari, Bo Wen, Duxin Sun, Shaomeng Wang
Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9. Journal of medicinal chemistry 67 (16) (2024)
Zhixiang Chen, Mi Wang, Dimin Wu, Longchuan Bai, Tianfeng Xu, Hoda Metwally, Yu Wang, Donna McEachern, Lijie Zhao, Ruiting Li, John Takyi-Williams, Meilin Wang, Lu Wang, Qiuxia Li, Bo Wen, Duxin Sun, Shaomeng Wang
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression. Journal of medicinal chemistry 67 (7) (2024)
Hualin Zhang, Yutong Tu, Zhaofan Tao, Lixin Gao, Shengjie Huang, Mingshan Gao, Jialuo Mao, Yang Zhou, Yupeng Li, Jia Li, Yubo Zhou, Tianfeng Xu
Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors. ACS medicinal chemistry letters 15 (8) (2024)
Chuan Zhou, Zisheng Fan, Yuejiao Gu, Zhiming Ge, Zhaofan Tao, Rongrong Cui, Yupeng Li, Guizhen Zhou, Ruifeng Huo, Mingshan Gao, Dan Wang, Wei He, Mingyue Zheng, Sulin Zhang, Tianfeng Xu
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS G12D . Journal of medicinal chemistry 67 (2) (2024)
Zhixiang Chen, Mi Wang, Dimin Wu, Longchuan Bai, Tianfeng Xu, Hoda Metwally, Yu Wang, Donna McEachern, Lijie Zhao, Ruiting Li, John Takyi-Williams, Meilin Wang, Lu Wang, Qiuxia Li, Bo Wen, Duxin Sun, Shaomeng Wang
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression. Journal of medicinal chemistry (2024)
Zehui Zhou, Guizhen Zhou, Chuan Zhou, Zisheng Fan, Rongrong Cui, Yupeng Li, Rui Li, Yuejiao Gu, Huajie Li, Zhiming Ge, Xiaojia Cai, Bing Jiang, Dan Wang, Mingyue Zheng, Tianfeng Xu, Sulin Zhang
Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers. Journal of medicinal chemistry (2023)
Meiying Liu, Guizhen Zhou, Wenhong Su, Yuejiao Gu, Mingshan Gao, Kun Wang, Ruifeng Huo, Yupeng Li, Zehui Zhou, Kaixian Chen, Mingyue Zheng, Sulin Zhang, Tianfeng Xu
Design, Synthesis, and Bioevaluation of Pyrido[2,3- d ]pyrimidin-7-ones as Potent SOS1 Inhibitors. ACS medicinal chemistry letters 14 (2) (2023)
Zehui Zhou, Guizhen Zhou, Chuan Zhou, Zisheng Fan, Rongrong Cui, Yupeng Li, Rui Li, Yuejiao Gu, Huajie Li, Zhiming Ge, Xiaojia Cai, Bing Jiang, Dan Wang, Mingyue Zheng, Tianfeng Xu, Sulin Zhang
Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers. Journal of medicinal chemistry 66 (6) (2023)
Xin Han, Lijie Zhao, Weiguo Xiang, Bukeyan Miao, Chong Qin, Mi Wang, Tianfeng Xu, Donna McEachern, Jianfeng Lu, Yu Wang, Hoda Metwally, Chao-Yie Yang, Paul D Kirchhoff, Lu Wang, Aleksas Matvekas, John Takyi-Williams, Bo Wen, Duxin Sun, Mark Ator, Robert Mckean, Shaomeng Wang
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. Journal of medicinal chemistry (2023)
Zhixiang Chen, Biao Hu, Rohan Kalyan Rej, Dimin Wu, Ranjan Kumar Acharyya, Mingliang Wang, Tianfeng Xu, Jianfeng Lu, Hoda Metwally, Yu Wang, Donna McEachern, Longchuan Bai, Christina L Gersch, Meilin Wang, Wenjing Zhang, Qiuxia Li, Bo Wen, Duxin Sun, James M Rae, Shaomeng Wang
Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity. Journal of medicinal chemistry (2023)
Weiguo Xiang, Lijie Zhao, Xin Han, Tianfeng Xu, Steven Kregel, Mi Wang, Bukeyan Miao, Chong Qin, Mingliang Wang, Donna McEachern, Jianfeng Lu, Longchuan Bai, Chao-Yie Yang, Paul D Kirchhoff, John Takyi-Williams, Lu Wang, Bo Wen, Duxin Sun, Mark Ator, Robert Mckean, Arul M Chinnaiyan, Shaomeng Wang
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer. Journal of medicinal chemistry (2023)
Zehui Zhou, Guizhen Zhou, Chuan Zhou, Zisheng Fan, Rongrong Cui, Yupeng Li, Rui Li, Yuejiao Gu, Huajie Li, Zhiming Ge, Xiaojia Cai, Bing Jiang, Dan Wang, Mingyue Zheng, Tianfeng Xu, Sulin Zhang
Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers. Journal of medicinal chemistry 66 (6) (2023)
Meiying Liu, Guizhen Zhou, Wenhong Su, Yuejiao Gu, Mingshan Gao, Kun Wang, Ruifeng Huo, Yupeng Li, Zehui Zhou, Kaixian Chen, Mingyue Zheng, Sulin Zhang, Tianfeng Xu
Design, Synthesis, and Bioevaluation of Pyrido[2,3- d ]pyrimidin-7-ones as Potent SOS1 Inhibitors. ACS medicinal chemistry letters 14 (2) (2023)
Hualin Zhang, Ruliang Xie, Hawaa Ai-Furas, Yupeng Li, Qingxia Wu, Jian Li, Fang Xu, Tianfeng Xu
Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation. ACS medicinal chemistry letters 13 (2) (2022)